A two-person startup called Saccade claims its 15-minute virtual reality eye test can detect Alzheimer's biomarkers up to 15 years before symptoms surface. The Y Combinator-backed company is entering a diagnostic race it may have already lost: blood tests have secured three FDA clearances in fourteen months and now run in hospital labs nationwide.
Saccade's founder, Shreyas Bhardwaj, is targeting longevity clinics and neurology practices at a moment when new drugs make early detection matter in ways it never did before. Leqembi and Kisunla, both approved to slow early-stage cognitive decline, work only if patients are diagnosed while still minimally symptomatic. That reality is pushing the Alzheimer's diagnostic industry out of specialty centers and into primary care, where the tools need to be fast, cheap, and scalable.
Blood biomarkers have compressed what used to be an odyssey. Diagnosis once required PET scans or spinal taps. Now it can happen with a blood draw.
Roche received FDA clearance on August 24, 2026, for its Elecsys pTau217 test, the first single-biomarker blood assay with validated cutoffs that work in both primary and specialty care settings, according to the company's announcement. The test runs on 4,500 cobas analyzers already humming in U.S. laboratories. "FDA clearance of Elecsys pTau217 marks an important milestone in Alzheimer's disease diagnosis," said Dan Malarek, president and CEO of Roche Diagnostics North America, in the sort of carefully calibrated statement that companies issue when they sense they've captured ground.
C2N Diagnostics filed for clearance in August 2026 and got it the following month for its PrecivityAD2 test. Fujirebio's Lumipulse plasma pTau217 test cleared in May 2025. Labcorp and Quest, the two giants of U.S. lab testing, launched laboratory-developed p-tau217 assays in March and April 2024, according to company announcements. "By expanding our test availability to include p-tau217 and other blood-based biomarkers, Quest has invested significantly in providing insights to aid risk assessment and early diagnosis," Kathleen Valentine, vice president and general manager of neurology at Quest Diagnostics, said in April 2024.
The Alzheimer's Association gave the field a stamp of legitimacy on July 29, 2025, releasing clinical practice guidelines that said tests with at least 90 percent sensitivity and specificity could substitute for PET scans or cerebrospinal fluid analysis in cognitively impaired patients receiving specialty care.
The Stakes Are Massive
An estimated 7.4 million Americans age 65 and older lived with Alzheimer's in 2026, according to the Alzheimer's Association's annual Facts and Figures report. Health and long-term care costs for people with dementia were projected at $409 billion, with Medicare and Medicaid covering nearly two-thirds. Over 55 percent of primary-care physicians reported insufficient dementia specialists in their communities, the same report found, underscoring the need for tools that can live in general practice rather than academic medical centers.
Leqembi received traditional FDA approval on July 6, 2023. Kisunla followed a year later, on July 2, 2024. Both drugs modestly slow cognitive decline in early Alzheimer's, but they require patients to enter treatment while symptoms are still mild. Medicare covers the therapies under a framework that mandates registry participation, a form of post-market surveillance. Leqembi later received additional approvals for subcutaneous maintenance dosing in August 2025 and subcutaneous initiation dosing in July 2026, which may ease the bottleneck at infusion centers that has slowed rollout.
A study published February 19, 2026, in Nature Medicine demonstrated that serial p-tau217 blood tests can estimate when initially asymptomatic adults will develop symptoms, with a margin of roughly three to four years. "This study shows that it is possible to use blood tests to predict not only if individuals are likely to develop Alzheimer's symptoms but also to estimate when the symptoms will begin," said Suzanne Schindler, an associate professor at Washington University School of Medicine and the study's senior author. The authors cautioned that the approach should remain limited to research settings for now.
Health Systems Move Fast
Hospitals didn't wait for perfect clarity. KU Health System launched its Brain Health Care Accelerator in April 2025, deploying a Lumipulse p-tau217 laboratory-developed test with 24-hour turnaround to support primary-care-centered diagnostic pathways, according to a case study published in May 2026. UC Health in Cincinnati reported that more than 95 percent of patients in its Brain Health Navigator program completed full pre-diagnosis workups, including p-tau217 or PrecivityAD panels, before specialty visits between July 2025 and February 2026. UCSF Memory & Aging Center published a case-based report in January 2025 outlining the logistics and diagnostic impact of clinic-deployed blood biomarkers.
Studies from memory clinics in 2025 and 2026 described real-world implementation in consecutive patient cohorts. Behavioral neurology practices reported that blood biomarkers improved diagnostic certainty and influenced medication decisions early in clinical adoption, though perhaps more slowly than the industry hoped.
Biogen reported that 13,388 individuals received at least one intravenous Leqembi infusion in a U.S. claims database through November 30, 2025. That figure, modest by blockbuster standards, underscores the monitoring and diagnostic workload now running through health systems.
Eye Tracking Enters the Picture
Saccade's approach draws on decades of research showing that saccadic eye movements go awry in Alzheimer's. A systematic review and meta-analysis published in May 2022 in Frontiers in Aging Neuroscience found that saccadic differences, including latency and error rates, robustly distinguish Alzheimer's and mild cognitive impairment from controls across paradigms. The authors positioned eye tracking as a potential low-cost biomarker suitable for wide implementation, though they called for further standardization and validation. Studies published in 2018 and 2023 documented increased antisaccade errors in prodromal Alzheimer's and amnestic mild cognitive impairment. Reviews in 2024 and 2025 noted that many ocular measures remain research tools and have not been qualified as routine diagnostic instruments.
Saccade administers five oculomotor tasks in approximately 15 minutes using a VR headset with what the company describes as a patent-pending eye-tracking attachment. The tasks include prosaccade, antisaccade, fixation, and smooth pursuit exercises. A machine-learning model analyzes eye-movement timing, accuracy, and control metrics to generate a risk analysis intended to guide referrals, according to the startup's Y Combinator profile and website. The company markets the test for repeat six-month follow-ups at longevity and neurology clinics.
The startup has not publicly posted peer-reviewed clinical validation data, regulatory filings, or the names of partner clinics, according to a review of available sources in October 2026. No published accuracy metrics, sample sizes, or prospective longitudinal results appeared in public sources accessed in October 2026.
Bhardwaj, the founder and CEO, previously built medical devices for hospitals and worked as a soft robotics researcher, according to his Y Combinator and LinkedIn profiles. He studied at UC Santa Barbara. The company launched in 2026.
Competitors pursuing ocular biomarkers include ViewMind, which has published studies on VR eye-tracking in asymptomatic familial Alzheimer's carriers and correlations with amyloid biomarkers. RetiSpec and Optina Diagnostics are both developing hyperspectral retinal imaging. RightEye and Neurolign offer FDA-cleared eye-tracking hardware for neurodiagnostics but do not market Alzheimer's-specific diagnostic claims.
The "Earliest Biomarker" Question
The claim that any single test can detect Alzheimer's biomarkers 15 years before symptoms remains an area of active scientific investigation. The National Institute on Aging and large reviews agree that Alzheimer's pathophysiology unfolds years, often decades, before overt symptoms. Blood biomarkers can now detect amyloid and tau positivity in pre-symptomatic individuals. Ocular measures show group-level abnormalities in mild cognitive impairment and prodromal Alzheimer's, but clinical qualification as the earliest diagnostic biomarkers is still under investigation.
Saccade's 15-year lead-time claim aligns with the general preclinical disease window. It is not yet substantiated by Saccade-specific clinical studies in public literature, according to a review of available sources in October 2026.
Regulatory and reimbursement pathways remain fluid. The FDA's attempt to regulate laboratory-developed tests was vacated by a federal district court on March 31, 2025, reverting enforcement to its pre-2024 posture. CLIA-certified labs continue to offer tests while device clearances proceed in parallel. Payer coverage for blood biomarkers remains heterogeneous across commercial plans and Medicare contractors, though the Alzheimer's Association's clinical practice guideline from 2025 is expected to inform medical-necessity criteria as insurers catch up.
The race between blood tests and alternative modalities will likely be decided by health-system adoption speed, reimbursement clarity, and prospective validation in longitudinal cohorts. Blood tests already run on installed analyzers. They deliver results in hours and carry FDA clearances with defined cutoffs. Eye-tracking and retinal imaging offer the appeal of non-invasive, point-of-care assessment, if they can deliver comparable accuracy and regulatory endorsement.
For now, clinics prioritizing throughput and payer acceptance are choosing blood. Saccade and its peers face not just a scientific challenge but a timing problem. They're racing against a technology that already has a head start and hospital infrastructure behind it.
